On December 2, 2019 Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, reported that Paul Rennert, Ph.D., President and Chief Scientific Officer, will deliver an oral presentation at the 61st ASH (Free ASH Whitepaper) Annual Meeting & Exposition, December 7 – 10, 2019, Orange County Convention Center, Orlando, FL (Press release, Aleta Biotherapeutics, DEC 2, 2019, View Source [SID1234551834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The 61st ASH (Free ASH Whitepaper) Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD19-anti-CD20 bridging protein technology," said Paul Rennert, Ph.D., President and Chief Scientific Officer of Aleta Biotherapeutics. "We look forward to advancing the development of this novel therapy based on the data we will be presenting on December 7."

Oral Presentation Details
Title: 252 A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment in vivo
Session Name: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Mechanisms
Presenter: Paul Rennert, Ph.D.
Session Date: Saturday, December 7, 2019
Session Time: 2:00 PM – 3:30 PM
Presentation Time: 3:15 PM
Location: Orange County Convention Center, Valencia A (W415A)